At the 44th annual conference of J.P. At the 2026 Morgan Healthcare Conference, Revolution Medicines CEO Mark A. Goldsmith attended a corporate presentation at 10:30 AM PT.[2] Investors gathered in room #JPM26 to hear the CEO answer questions about the potential acquisition.[1] Shares of Revolution Medicines surged 29% following news of advanced takeover talks with AbbVie.[1] Trading in the stock was suspended twice due to high volatility.[1] The expected value of the acquisition is around $20 billion, a premium over the current market value of around $16 billion.[1] The news impacted the oncology biotech sector, with shares of Verastem up 25%, Tango Therapeutics up 20% and Erasca up 27%.[1] Revolution Medicines specializes in the development of targeted therapies for RAS-dependent cancers, including inhibitors such as daraxonrasib (RMC-6236), elironrasib (RMC-6291), zoldonrasib (RMC-9805) and others in clinical development.[2] There is no official confirmation of the acquisition from both companies yet.[1]